Table 1

 Demographic and clinical data from the 49 patients included in the study: 24 patients with SpA, 15 with rheumatoid arthritis (RA), and 10 with OA

DataSpA (n = 24)RA (n = 15)OA (n = 10)
Mean(range)Mean(range)Mean(range)
All patients had active disease with at least one swollen knee joint. Among the 24 patients with SpA, nine were studied also after 12 weeks of treatment with the monoclonal anti-TNFα antibody, infliximab.
*The following synovial histology parameters were evaluated: lining, microscopic evaluation of the lining layer thickness ranging from 1 (layer of 1–2 cells) to 2 (layer of 4–5 cells) to 3 (layer of >5 cells); vascularisation, degree of vascularisation scored from 0 to 3; infiltration, degree of cellular infiltration scored from 0 to 3; lymphoid aggregates, presence of lymphoid aggregates scored from 0 (absent) to 1 (present); plasma cells, presence of plasma cells scored from 0 (absent) to 3 (multiple cells within the entire synovium); polymorphonuclear cells, presence of polymorphonuclear cells within the synovium scored from 0 (absent) to 3 (multiple cells within the entire synovium); immunoreactivities of CD3+, T cell marker (anti-CD3 monoclonal antibody, DAKO), and CD20+, B cell marker (anti-CD20 monoclonal antibody, DAKO) were graded from 0 to 3.
Age (years)47(19–66)63(40–74)62(29–87)
Sex (M/F)18/68/75/5
Disease duration (years)3(0.1–42)2(0.1–20)2(0.1–35)
HLA-B27 (+/−)12/12NANA
Swollen joint count2(1–24)6(1–25)1(1–2)
CRP (mg/l)22(4–167)60(16–550)0(0–72)
ESR (mm/1st h)24(3–101)48(7–90)4(1–37)
Lining*1(1–2)1(1–3)1(1–2)
Vascularisation*2(1–3)1.3(1–2.5)1(0–2)
Infiltration*2(0–3)2(0.5–3)0.5(0–1)
Lymphoid aggregates*0.5(0–2)1(1–2)0(0–1)
Plasma cells*0(0–3)0.3(0–2)0(0)
Polymorphonuclear cells*0(0–3)0(0–2.5)0(0)
CD3+*1.5(0–3)2(0–3)1(0–3)
CD20+*1(0–3)2(0–2.5)0(0–2)